Navigation Links
OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is Feasible in Patients Requiring Undeferrable Non-Cardiac Surgery, International Journal of Cardiology Publication Reports
Date:9/11/2009

HONG KONG, Sept. 11 /PRNewswire/ -- OrbusNeich's Genous Bio-engineered R stent is feasible and safe in patients who need coronary revascularization before undeferrable non-cardiac surgery and have to discontinue dual antiplatelet therapy, according to a paper published online in the International Journal of Cardiology (Int J Cardiol. 2009 Aug 21. [Epub ahead of print]).

The paper, titled "A new approach to percutaneous coronary revascularization in patients requiring undeferrable non-cardiac surgery," is based on a study of 30 patients who needed coronary revascularization followed by an endovascular or surgical procedure. All of the patients were treated with the Genous stent, and there were no cardiac events reported at 30-days follow-up after surgery. The dual antiplatelet therapy was stopped before surgery, achieving an average antiplatelet therapy time of 12.2 +/- 3.9 days. The surgery was performed after antiplatelet therapy interruption at an average interval from revascularization of 17.2 +/- 3.9 days.

"The literature on an optimal strategy for high cardiovascular risk patients requiring undeferrable surgery remains limited," said Federico Piscione, M.D., of Federico II University in Naples, Italy, lead and corresponding author of the publication. "This study adds to the body of knowledge that this Genous healing stent could allow surgical procedures to be performed soon after stent deployment and DAT (dual antiplatelet therapy) discontinuation."

About Genous

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the placement of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis
'/>"/>

SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients
2. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
3. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
4. Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients
5. Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. New Call Center Helps Ovarian Cancer Patients Cope With Challenges of Diagnosis
8. New Insights Link Low HDL-Cholesterol and Elevated Triglycerides With Coronary Heart Disease and Microvascular Complications in Patients at Goal for LDL-Cholesterol
9. Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
10. Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
11. Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- , The first grants awarded to ... (ESPE) Meeting  Investment supports innovative projects for ... field of growth  , EMD Serono, a ... , today announced the first recipients of the Grant ... announced during a Satellite Symposium organized by EMD Serono ...
(Date:9/18/2014)... About POCT POCT, ... clinical laboratory. It helps in making fast clinical ... medication. POCT is gaining popularity due to the ... as diabetes, heart disease, and obesity. It is ... to minimize errors during the diagnosis of patients. ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... -- Research and Markets has announced ... Report 2014" report to their offering. ... is a professional and in-depth study on the ... The report provides a basic overview of ... chain structure. The N-acetylcysteine market analysis is provided ...
Breaking Biology Technology:EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2
... 14 LI-COR Biosciences introduces a,new, novel protein ... Imaging system. The Odyssey Two-Color Protein Molecular Weight,Marker ... 800 nm channels of the,Odyssey System. The marker ... be used to visualize the progress of protein ...
... National Drug Control Policy to Moderate ... Bad Drugs, FRAZER, Pa., Oct. 14 ... embarking on a national educational,program designed to promote ... the importance of appropriate and responsible use of,prescription ...
... ProtoKinetix (OTC,Bulletin Board: PKTX), a biotech ... of patented anti-aging glycopeptides,(AAGPs(TM)), announced today that ... a division of National Financial Communications Corp.,(NFC), ... "ProtoKinetix, AAGP(TM) platform technology is ideal ...
Cached Biology Technology:LI-COR Introduces the Odyssey(R) Two-Color NIR Fluorescent Protein Molecular Weight Marker 2Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications 2ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base 2ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base 3
(Date:9/18/2014)... people are too stressed they are often grouchy, grumpy, ... Institute (BMI) at EPFL have just highlighted a fundamental ... and the loss of social skills and cognitive impairment. ... regulatory molecule in the brain. This was revealed by ... , Carmen Sandi,s team went to look for answers ...
(Date:9/18/2014)... Clownfish spend their entire lives nestling in the protective ... as babies they sometimes travel hundreds of kilometres across ... by reef fish has been predicted, this is the ... between distant populations has been observed. , Dr Steve ... at the University of Exeter, and colleagues from the ...
(Date:9/17/2014)... student have designed a device based on a shorebird,s ... dew., The device could provide water in drought-stricken areas ... Luo, professor in the Mechanical & Aerospace Engineering Department, ... of Engineering department, published "Bioinspired Plate-Based Fog Collectors" in ... Applied Materials & Interfaces journal. ...
Breaking Biology News(10 mins):How stress tears us apart 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3Shorebird's beak inspires UT Arlington research on water collection 2
... 23andMe, the leading personal genetics company, announces the ... Neil Rothstein as Vice President Marketing, and Jonathan ... company,s executive leadership team. As ... the company,s corporate communications, media relations and investor ...
... Oct. 17, 2012 Rising crime rates and ... increase monitoring and introduce reliable border control systems. ... criminal identification and automated immigration at all entry ... adoption in the government vertical across Asia-Pacific. ...
... 24, 2012  Aware, Inc. (NASDAQ: AWRE ), ... assurance products, today reported financial results for its third ... our DSL service assurance hardware business have been reported ... the shutdown of that business during the third quarter. ...
Cached Biology News:23andMe Names Christine Castro, Neil Rothstein and Jonathan Ward to Leadership Positions 2Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 2Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 3Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 4Aware, Inc. Reports Third Quarter 2012 Financial Results 2Aware, Inc. Reports Third Quarter 2012 Financial Results 3Aware, Inc. Reports Third Quarter 2012 Financial Results 4Aware, Inc. Reports Third Quarter 2012 Financial Results 5Aware, Inc. Reports Third Quarter 2012 Financial Results 6
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
... has a long and outstanding history ... Several years ago we became aware ... was being modified to inject Xenopus ... redesigning the microdispenser to eliminate any ...
...
... designed for sequencing inserts cloned into M13/pUC-based ... T3 RNA polymerase promoters, or lambda gt10 ... a concentration of 0.1 µg/µl in water. ... sequencing reactions using SequiTherm™ EXCEL™ II DNA ...
Biology Products: